Drug Trial Radar · NCT00741585
Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment
Last checked: Nov 19, 2026Latest source record: Aug 28, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21,983
Actual
Start
Sep 1, 2008
Primary completion
Jun 30, 2018
Study completion Jun 30, 2018
Sponsor
- Lead sponsor
- University of VigoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Servicio Gallego de Salud
- First posted
- Aug 26, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The HYGIA study was designed to investigate prospectively 1. the prognostic value of ambulatory blood pressure (BP) monitoring among subjects primarily evaluated at primary care settings 2. the impact of changes in ambulatory BP during follow-up in cardiovascular, cerebrovascular, metabolic, and renal risk in hypertensive patients 3. the influence of circadian time of treatment in cardiovascular, cerebrovascular, metabolic, and renal risk in hypertensive patients 4. the prevalence of an altered BP profile as a function of antihypertensive treatment, circadian time of treatment, age, and presence of diabetes, among other factors.
Conditions
- Essential Hypertension
- Cardiovascular Disease
- Stroke
- Chronic Kidney Disease
Interventions
Any antihypertensive medication alone or in combinationDrug
All drugs on awakening
Any antihypertensive medication alone or in combinationDrug
One or more drugs at bedtime
Ambulatory blood pressure monitoringDevice
Sampling at 20-min intervals from 07:00 to 23:00 and at 30-min intervals at night for 48 consecutive hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the impact of circadian time of treatment in cardiovascular, cerebrovascular, metabolic, and renal risk assessment.Time frame: Yearly evaluation for at least ten years
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
CS Fingoi
Lugo, Spain
Complexo Hospitalario Universitario de Ourense
Ourense, Spain
CS Lerez
Pontevedra, Spain
CS Friol
Friol, Lugo, Spain
CS A Estrada
A Estrada, Pontevedra, Spain
CS Baiona
Baiona, Pontevedra, Spain
CS Bueu
Bueu, Pontevedra, Spain
CS A Guarda
La Guardia, Pontevedra, Spain
CS Valmiñor
Nigrán, Pontevedra, Spain
CS Panxón
Nigrán, Pontevedra, Spain
CS Tomiño
Tomiño, Pontevedra, Spain
Bioengineering & Chronobilogy Labs., University of Vigo
Vigo, Pontevedra, Spain
Hospital do Meixoeiro
Vigo, Pontevedra, Spain
CS Calle Cuba
Vigo, Pontevedra, Spain
CS A Doblada
Vigo, Pontevedra, Spain
CS Coia
Vigo, Pontevedra, Spain
CS Sardoma
Vigo, Pontevedra, Spain
CS Teis
Vigo, Pontevedra, Spain
CS Vilaboa
Vilaboa, Pontevedra, Spain
CS San Roque
Vilagarcía de Arousa, Pontevedra, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.